Sharon Munn

4.5k total citations · 1 hit paper
24 papers, 2.3k citations indexed

About

Sharon Munn is a scholar working on Health, Toxicology and Mutagenesis, Small Animals and Computational Theory and Mathematics. According to data from OpenAlex, Sharon Munn has authored 24 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Health, Toxicology and Mutagenesis, 7 papers in Small Animals and 5 papers in Computational Theory and Mathematics. Recurrent topics in Sharon Munn's work include Effects and risks of endocrine disrupting chemicals (9 papers), Animal testing and alternatives (7 papers) and Computational Drug Discovery Methods (5 papers). Sharon Munn is often cited by papers focused on Effects and risks of endocrine disrupting chemicals (9 papers), Animal testing and alternatives (7 papers) and Computational Drug Discovery Methods (5 papers). Sharon Munn collaborates with scholars based in Italy, United States and Canada. Sharon Munn's co-authors include Daniel L. Villeneuve, Maurice Whelan, Brigitte Landesmann, M.E. Meek, Alan R. Boobis, Jennifer Seed, Carolyn Vickers, Carlie A. LaLone, Markus Hecker and Doug Crump and has published in prestigious journals such as Pure and Applied Chemistry, Toxicology and Applied Pharmacology and Toxicological Sciences.

In The Last Decade

Sharon Munn

23 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adverse Outcome Pathway (AOP) Development I: Strategies and Principles

2014 488 citations Daniel L. Villeneuve, Doug Crump et al. Toxicological Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sharon Munn Italy	17	1.1k	481	416	398	365	24	2.3k
Alicia Paini Italy	25	780 0.7×	388 0.8×	346 0.8×	340 0.9×	420 1.2×	79	2.0k
Barbara A. Wetmore United States	30	1.6k 1.5×	531 1.1×	561 1.3×	574 1.4×	666 1.8×	60	2.8k
Daniel M. Rotroff United States	26	1.3k 1.2×	910 1.9×	768 1.8×	401 1.0×	547 1.5×	90	3.4k
Michelle R. Embry United States	30	1.6k 1.5×	322 0.7×	233 0.6×	282 0.7×	319 0.9×	76	2.6k
Michael W. Hornung United States	23	2.3k 2.1×	679 1.4×	452 1.1×	310 0.8×	322 0.9×	48	4.1k
Nynke I. Kramer Netherlands	24	847 0.8×	286 0.6×	213 0.5×	203 0.5×	262 0.7×	66	1.9k
Patricia K. Schmieder United States	18	1.4k 1.3×	474 1.0×	530 1.3×	178 0.4×	265 0.7×	38	2.7k
Nisha S. Sipes United States	30	1.7k 1.6×	1.2k 2.5×	780 1.9×	393 1.0×	610 1.7×	48	3.8k
Scott S. Auerbach United States	31	891 0.8×	1.1k 2.3×	522 1.3×	430 1.1×	246 0.7×	94	2.8k
M.E. Meek Canada	27	1.8k 1.6×	580 1.2×	417 1.0×	1.1k 2.8×	479 1.3×	99	3.6k

Countries citing papers authored by Sharon Munn

Since Specialization

Citations

This map shows the geographic impact of Sharon Munn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Munn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Munn more than expected).

Fields of papers citing papers by Sharon Munn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Munn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Munn. The network helps show where Sharon Munn may publish in the future.

Co-authorship network of co-authors of Sharon Munn

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Munn. A scholar is included among the top collaborators of Sharon Munn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Munn. Sharon Munn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gourmelon, Anne, P. Hubert, Elise Grignard, et al.. (2024). The benefits of validation of methods for toxicity testing outweigh its costs. ALTEX. 41(3). 395–401. 2 indexed citations

Carnesecchi, Edoardo, Patience Browne, Sofia Batista Leite, et al.. (2023). OECD harmonised template 201: Structuring and reporting mechanistic information to foster the integration of new approach methodologies for hazard and risk assessment of chemicals. Regulatory Toxicology and Pharmacology. 142. 105426–105426. 15 indexed citations

Pistollato, Francesca, Federica Madia, Raffaella Corvi, et al.. (2021). Current EU regulatory requirements for the assessment of chemicals and cosmetic products: challenges and opportunities for introducing new approach methodologies. Archives of Toxicology. 95(6). 1867–1897. 82 indexed citations

Grignard, Elise, Helen Håkansson, & Sharon Munn. (2020). Regulatory needs and activities to address the retinoid system in the context of endocrine disruption: The European viewpoint. Reproductive Toxicology. 93. 250–258. 29 indexed citations

Bal‐Price, Anna, Francesca Pistollato, Magdalini Sachana, et al.. (2018). Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods. Toxicology and Applied Pharmacology. 354. 7–18. 98 indexed citations

Andersson, Niklas, Maria Arena, Domenica Auteri, et al.. (2018). Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. EFSA Journal. 16(6). e05311–e05311. 275 indexed citations

Knapen, Dries, Michelle Angrish, Marie Fortin, et al.. (2018). Adverse outcome pathway networks I: Development and applications. Environmental Toxicology and Chemistry. 37(6). 1723–1733. 165 indexed citations

Odum, J., et al.. (2017). Adverse Outcome Pathway: Peroxisome Proliferator-Activated Receptor α Activation and Reproductive Toxicity—Development and Application in Assessment of Endocrine Disruptors/Reproductive Toxicants. Joint Research Centre (European Commission). 3(3). 234–249. 8 indexed citations

LaLone, Carlie A., Gerald T. Ankley, Scott E. Belanger, et al.. (2017). Advancing the adverse outcome pathway framework—An international horizon scanning approach. Environmental Toxicology and Chemistry. 36(6). 1411–1421. 56 indexed citations

10.

Kleinstreuer, Nicole, Kristie Sullivan, David Allen, et al.. (2016). Adverse outcome pathways: From research to regulation scientific workshop report. Regulatory Toxicology and Pharmacology. 76. 39–50. 46 indexed citations

11.

Horvat, Tomislav, Brigitte Landesmann, Alfonso Lostia, et al.. (2016). Adverse outcome pathway development from protein alkylation to liver fibrosis. Archives of Toxicology. 91(4). 1523–1543. 35 indexed citations

12.

Gerloff, Kirsten, Brigitte Landesmann, Andrew Worth, et al.. (2016). The Adverse Outcome Pathway approach in nanotoxicology. Computational Toxicology. 1. 3–11. 79 indexed citations

13.

Munn, Sharon, Brigitte Landesmann, Alivia Lee Price, et al.. (2015). Using AOPs to transition to alternative approaches to predict toxicity. Toxicology Letters. 238(2). S180–S180. 1 indexed citations

14.

Villeneuve, Daniel L., Doug Crump, Natàlia García‐Reyero, et al.. (2014). Adverse Outcome Pathway (AOP) Development I: Strategies and Principles. Toxicological Sciences. 142(2). 312–320. 488 indexed citations breakdown →

15.

Villeneuve, Daniel L., Doug Crump, Natàlia García‐Reyero, et al.. (2014). Adverse Outcome Pathway Development II: Best Practices. Toxicological Sciences. 142(2). 321–330. 180 indexed citations

16.

Meek, M.E., Alan R. Boobis, Ila Cote, et al.. (2013). New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. Journal of Applied Toxicology. 34(1). 1–18. 198 indexed citations

17.

Hoekstra, Eddo J., et al.. (2010). Bisphenol A and baby bottles: challenges and perspectives. Joint Research Centre (European Commission). 24 indexed citations

18.

Boobis, Alan R., John E. Doe, Barbara Heinrich-Hirsch, et al.. (2008). IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans. Critical Reviews in Toxicology. 38(2). 87–96. 395 indexed citations

19.

Christensen, Frans M., et al.. (2003). Assessment Tools under the New European Union Chemicals Policy. Greener Management International. 2003(41). 5–19. 17 indexed citations

20.

Munn, Sharon & Björn Hansen. (2002). EU risk assessment: science and policy. Toxicology. 181-182. 281–285. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact